血管扩张剂负荷SPECT心肌灌注显像对心肌生物标志物升高患者的危险分层
该研究纳入503例7天内心肌生物标志物升高并接受血管扩张剂负荷SPECT MPI的患者,随访平均33.6个月。
要点
- 血管扩张剂负荷SPECT MPI可有效对近期心肌生物标志物升高患者进行危险分层。
- MPI结果在临床因素和肌钙蛋白升高程度之外提供增量预后价值。
核心结论
- 血管扩张剂负荷(包括瑞加德松)SPECT MPI能有效对近期心肌生物标志物升高的患者进行危险分层,灌注缺损越严重死亡风险越高。
- MPI在临床危险因素和肌钙蛋白升高程度之外提供增量预后价值,应激TPD对全因和心脏死亡均保持独立预测作用。
研究设计与样本
- 回顾性研究,纳入两家三级中心2010年1月1日至2012年12月31日期间7天内心肌生物标志物升高并接受负荷SPECT MPI的患者,共503例,平均随访33.6±16.2个月。
- 负荷MPI采用17节段半定量评分,按总灌注缺损(TPD)分为正常(0%)、轻度(1-10%)、中度(10-20%)和重度(>20%)。
- 主要终点为全因死亡率,次要终点为心脏死亡率,死亡数据来自国家死亡索引至2014年。
主要发现
- 503例患者平均年龄69.3岁,53.7%为男性,88.7%接受血管扩张剂负荷。
- 调整心脏危险因素、既往冠心病和肌钙蛋白四分位数后,上述关联仍维持。
- MPI结果(应激TPD和LVEF)加入传统心脏危险因素和肌钙蛋白值后,对全因和心脏死亡率的预测能力显著增量提高。
- 多变量模型中应激TPD对全因和心脏死亡率均保持独立预测作用。
临床怎么用
- 对近期心肌生物标志物升高(7天内)的患者,可考虑行血管扩张剂负荷SPECT MPI以进行危险分层。
- 根据TPD严重程度(正常、轻度、中度、重度)评估死亡风险,指导后续临床决策。
- MPI结果应结合临床危险因素和肌钙蛋白水平综合解读,以提供增量预后信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although the diagnostic accuracy and prognostic utility of vasodilator stress MPI have been well established in the non-acute setting, the efficacy of all of the vasodilator stressors in risk stratifying post-MI patients as well as the evaluation of cardiac troponin elevation of unclear etiology is not established. Accordingly, the aim of the present study was to investigate the prognostic efficacy of vasodilator stress MPI in the setting of elevated cardiac troponin to accurately risk stratify these higher-risk patients. METHODS: All patients from two tertiary centers, from 1/1/2010 through 12/31/2012, with elevated cardiac biomarkers within < 7 days and undergoing stress SPECT MPI testing were studied. Results of stress MPI were scored using a 17-segment model based on semiquantitative scoring as normal or abnormal (mild, moderate, or severe) using a total perfusion defect (TPD) of 0%, 1-10%, 10-20%, and > 20%. Mortality data through the year 2014 were obtained from the National Death Index, and survival analyses were performed. The primary endpoint was all-cause mortality with the secondary endpoint being cardiac mortality. RESULTS: A total of 503 patients were followed for an average of 33.6 ± 16.2 months, with a mean age of 69.3 years; 53.7% male; and a majority (88.7%) of them undergoing vasodilator stress. A significant increase in all-cause mortality was seen based on the severity of TPD results for all vasodilators (P < .0001) and regadenoson (P < .0001). Similar prognostic ability was seen for all-cause mortality. This association was maintained even after adjustment for cardiac risk factors, previous coronary disease, and troponin quartiles. MPI results (stress TPD and LVEF) added to traditional cardiac risk factors, and troponin values resulted in a significant incremental increase in the ability to predict all-cause and cardiac mortality, and stress TPD remained independently predictive for both all-cause and cardiac mortality in a multivariate model. CONCLUSION: Vasodilator stress (including regadenoson) MPI effectively risk stratifies patients with recently elevated cardiac biomarkers, with the increasing risk of mortality with the increasing severity of perfusion defects. It provides incremental prognostic value, in addition to clinical factors and degree of troponin elevation.
引用
- Gowdar S, Ahlberg AW, Rai M, et al. Risk stratification with vasodilator stress SPECT myocardial perfusion imaging in patients with elevated cardiac biomarkers. J Nucl Cardiol. 2019. PMID: 30815834. doi:10.1007/s12350-019-01661-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。